EUVIMEDEUVIMED entdecken
BeobachtungsstudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Treatment and outcomes of clear cell sarcoma of the kidney: A report from the Children's Oncology Group studies AREN0321 and AREN03B2

Daniel J Benedetti iD, Lindsay A Renfro, Ian Tfirn, Najat C Daw, John A Kalapurakal, Peter F Ehrlich iD, Geetika Khanna, Elizabeth Perlman, Anne Warwick, Kenneth W Gow, Arnold C Paulino iD, Nita L Seibel iD und 5 weitere

Cancer · 2024-07 · 130 (13) · 2361-2371

DOI: 10.1002/cncr.35266 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cancer, online erschienen am 23.02.2024. Verfasst von Daniel J Benedetti und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Kidney Neoplasms, Sarcoma, Clear Cell, Vincristine. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, St Baldrick's Foundation, Solder True Life Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

On the fifth National Wilms Tumor Study, treatment for clear cell sarcoma of the kidney (CCSK) included combined vincristine, doxorubicin, cyclophosphamide, and etoposide (regimen I) plus radiation therapy (RT), yielding 5‐year event‐free survival (EFS) rates of 100%, 88%, 73%, and 29% for patients who had with stage I, II, III, and IV disease, respectively. In the Children’s Oncology Group study AREN0321 of risk‐adapted therapy, RT was omitted for stage I disease if lymph nodes were sampled, and carboplatin was added for stage IV disease (regimen UH‐1). Patients who had stage II/III disease received regimen I with RT.

Methods

Four‐year EFS was analyzed for patients enrolled on AREN0321 and on those enrolled on AREN03B2 who received AREN0321 stage‐appropriate chemotherapy.

Results

Eighty‐two patients with CCSK enrolled on AREN0321, 50 enrolled on AREN03B2 only. The 4‐year EFS rate was 82.7% (95% confidence interval [CI], 74.8%–91.4%) for AREN0321 and 89.6% (95% CI, 81.3%–98.7%) for AREN03B2 only ( p = .28). When combining studies, the 4‐year EFS rates for patients who had stage I ( n = 10), II ( n = 47), III ( n = 65), and IV ( n = 10) disease were 90% (95% CI, 73.2%–100.0%), 93.4% (95% CI, 86.4%–100.0%), 82.8% (95% CI, 74.1%–92.6%), and 58.3% (95% CI, 34%–100.0%), respectively. There were no local recurrences among seven patients with stage I disease who were treated without RT. One stage I recurrence occurred in the brain, which was the most common site of relapse overall. Among patients with local stage III tumors, neither initial procedure type, margin status, nor lymph node involvement were prognostic.

Conclusions

Patients with stage I CCSK had excellent outcomes without local recurrences when treated without RT. Patients with stage IV disease appeared to benefit from a carboplatin‐containing regimen, although their outcomes remained unsatisfactory. Further research is needed to improve outcomes for patients with advanced‐stage disease (ClinicalTrials.gov identifiers NCT00335556 and NCT00898365).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsKidney NeoplasmsSarcoma, Clear CellVincristineAdolescentChildChild, PreschoolFemaleHumansInfantMaleCarboplatinCyclophosphamideDisease-Free SurvivalDoxorubicinEtoposideNeoplasm StagingTreatment Outcome

Stichwörter der Autor:innen

brain metastasescarboplatinclear cell sarcoma of the kidney (CCSK)radiotherapy

Substanzen

CarboplatinCyclophosphamideDoxorubicinEtoposideVincristine

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Division of Biostatistics, University of Southern California, Los Angeles, California, USA.
  • Children's Oncology Group, Monrovia, California, USA.
  • Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Radiation Oncology, Northwestern University, Chicago, Illinois, USA.
  • Section of Pediatric Surgery, University of Michigan, Ann Arbor, Michigan, USA.

ORCID-Profile: Daniel J Benedetti, Peter F Ehrlich, Arnold C Paulino, Nita L Seibel, Paul Grundy, James I Geller

Förderung

  • NCI NIH HHS
  • St Baldrick's Foundation
  • Solder True Life Foundation

Zitieren

APA

Benedetti, D. J., Renfro, L. A., Tfirn, I., Daw, N. C., Kalapurakal, J. A., Ehrlich, P. F., Khanna, G., Perlman, E., Warwick, A., Gow, K. W., Paulino, A. C., Seibel, N. L., Grundy, P., Fernandez, C. V., Geller, J. I., Mullen, E. A., & Dome, J. S. (2024). Treatment and outcomes of clear cell sarcoma of the kidney: A report from the Children's Oncology Group studies AREN0321 and AREN03B2. Cancer, 130(13), 2361-2371. https://doi.org/10.1002/cncr.35266

Vancouver

Benedetti DJ, Renfro LA, Tfirn I, Daw NC, Kalapurakal JA, Ehrlich PF, et al. Treatment and outcomes of clear cell sarcoma of the kidney: A report from the Children's Oncology Group studies AREN0321 and AREN03B2. Cancer. 2024;130(13):2361-2371. doi:10.1002/cncr.35266

BibTeX
@article{Benedetti2024,
  author = {Benedetti, Daniel J and Renfro, Lindsay A and Tfirn, Ian and Daw, Najat C and Kalapurakal, John A and Ehrlich, Peter F and Khanna, Geetika and Perlman, Elizabeth and Warwick, Anne and Gow, Kenneth W and Paulino, Arnold C and Seibel, Nita L and Grundy, Paul and Fernandez, Conrad V and Geller, James I and Mullen, Elizabeth A and Dome, Jeffrey S},
  title = {Treatment and outcomes of clear cell sarcoma of the kidney: A report from the Children's Oncology Group studies AREN0321 and AREN03B2},
  journal = {Cancer},
  year = {2024},
  volume = {130},
  number = {13},
  pages = {2361--2371},
  doi = {10.1002/cncr.35266}
}
Kostenlos starten →